

# AZD2932

Catalog No: tcsc3356



## Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



## Specifications

### CAS No:

883986-34-3

### Formula:

$C_{24}H_{25}N_5O_4$

### Pathway:

Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK;Protein Tyrosine Kinase/RTK

### Target:

VEGFR;FLT3;PDGFR;c-Kit

### Purity / Grade:

>98%

### Solubility:

DMSO :  $\geq 41$  mg/mL (91.62 mM)

### Observed Molecular Weight:

447.49

## Product Description


AZD2932 is a potent and multi-targeted kinase inhibitor **VEGFR2**, **PDGFβ**, **Flt-3** and **c-Kit** with **IC<sub>50</sub>**s of 8, 4, 7 and 9 nM in cell

assay, respectively.

IC50 & Target: IC50: 8 nM (VEGFR2), 4 nM (PDGFβ), 7 nM (Flt-3), 9 nM (c-Kit)<sup>[1]</sup>

**In Vitro:** AZD2932 has a potent and balanced profile against PDGFβ, VEGFR-2, Flt-3 and c-Kit. It does not inhibit the various cytochrome P450 isoforms with the worst IC<sub>50</sub> being against 2C9 (8.0 μM). AZD2932 has no activity against hERG (IC<sub>50</sub>=137 μM)<sup>[1]</sup>.

**In Vivo:** Twice daily oral dosing (b.i.d.) of AZD2932 10 h apart results in significant tumor growth inhibition of 64% for both 50 and 12.5 mg/kg doses on the day the control animals are terminated. Xenografts bearing non PDGFβ expressing tumor cells are also sensitive to AZD2932 treatment: growth of Calu-6 tumor is inhibited by 81% and 72% at 50 and 12.5 mg/kg b.i.d. and and LoVo tumors by 67% at 50 mg/kg b.i.d. This is due AZD2932 potent activity against VEGFR2 as well as a potential effect on pericytes and tumor-associated fibroblasts due to PDGFR a and b inhibition. AZD2932 at 3-50 mg/kg b.i.d. 10 h apart gives 60-80% inhibition of both p-VEGFR2 and p-PDGFβ in a 1:1 ratio<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!